Latest 2024 prices and treatment options for Apelvis

Alpelisib , trade name Piqray, is an innovative drug that targets specific types of breast cancer. The drug is particularly suitable for women, and some men, who have gone through menopause or whose cancer has worsened during other treatments. Apelvis is unique in that it is used in combination with fulvestrant to effectively treat breast cancer that has spread to nearby tissue or other parts of the body.

Apelvis belongs to the kinase inhibitor class of drugs, which exerts therapeutic effects by blocking the signaling pathways that allow cancer cells to reproduce. This mechanism helps inhibit the spread of cancer cells, thereby providing patients with better treatment opportunities.

However, the original drug of Apelvis has not yet been launched in China, so its price information is not clear in China. However, some relevant information can be learned from overseas markets. The specifications of the European version of Apelvis are 150mg*56 tablets per box, and the price may be as high as more than 40,000 yuan. The specifications of the Indian version are 150mg*28 tablets per box, and the price is relatively low, probably around 5,000 yuan. Of course, these prices may fluctuate due to exchange rates.

It is worth mentioning that generic drugs of Apelvis have appeared in overseas markets. The ingredients of these drugs are basically the same as the original drugs, but the prices are more affordable. For example, the generic version of Apelvis produced by a Lao pharmaceutical factory is 150mg*28 tablets per box, and the price may be around 2,000 yuan. This provides more treatment options for patients with limited financial resources.

Overall, Apelvis, as an innovative drug, provides new treatment opportunities for patients with specific types of breast cancer. Although its price in China is not yet clear, price information in overseas markets can provide us with a certain reference. At the same time, the emergence of generic drugs also provides patients with more economic choices.